Publication Title
Ther Clin Risk Manag
Document Type
Article
Publication Date
1-1-2018
Keywords
BRCA; PARP inhibitor; ovarian cancer; rucaparib; targeted therapy
Abstract
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration's (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Although cytoreductive surgery and (platinum/taxane-based) chemotherapy can place the majority of patients into remission, most will experience a relapse of their disease in their lifetime. This has led to studies exploring the benefits and efficacy of maintenance treatment. This review will briefly discuss the history of maintenance therapy as well as focus on the FDA's approval of rucaparib and its companion tumor profiling test, in the US. It will describe how women with deleterious mutations in the
Clinical Institute
Cancer
Clinical Institute
Women & Children
Specialty
Oncology
Specialty
Obstetrics & Gynecology
